These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 6681406)

  • 1. 2nd International symposium of the Society of Toxicologic Pathologists. Design of carcinogenicity studies: considerations in pathology interpretation. May 9-11, 1983, Arlington, Virginia.
    Toxicol Pathol; 1983; 11(2):132-207. PubMed ID: 6681406
    [No Abstract]   [Full Text] [Related]  

  • 2. 2nd International symposium of the Society of Toxicologic Pathologists. Design of carcinogenicity studies: considerations in pathology interpretation. May 9-11, 1983, Arlington, Virginia.
    Toxicol Pathol; 1983; 11(1):28-95. PubMed ID: 6681393
    [No Abstract]   [Full Text] [Related]  

  • 3. Estimating human safety from animal tumor data. Third International Symposium of the Society of Toxicology Pathologists. Arlington, Virginia, May 14-16, 1984.
    Toxicol Pathol; 1985; 13(2):83-170. PubMed ID: 4048770
    [No Abstract]   [Full Text] [Related]  

  • 4. Considerations in the interpretation of animal bioassays for chemical carcinogenicity.
    Griesemer RA
    Transplant Proc; 1984 Apr; 16(2):412-5. PubMed ID: 6372175
    [No Abstract]   [Full Text] [Related]  

  • 5. Epidemiology of occupational carcinogens and mutagens.
    Ruder AM
    Occup Med; 1996; 11(3):487-512. PubMed ID: 8887381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Society of toxicologic pathology position on assessment of hyperplastic lesions in rodent carcinogenicity studies.
    Boorman G; Dixon D; Elwell M; Kerlin R; Morton D; Peters T; Regan K; Sullivan J;
    Toxicol Pathol; 2004; 32(1):124-5. PubMed ID: 14713557
    [No Abstract]   [Full Text] [Related]  

  • 7. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
    Gaylor DW
    Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Issues in the design and interpretation of chronic toxicity and carcinogenicity studies in rodents: approaches to dose selection.
    Rhomberg LR; Baetcke K; Blancato J; Bus J; Cohen S; Conolly R; Dixit R; Doe J; Ekelman K; Fenner-Crisp P; Harvey P; Hattis D; Jacobs A; Jacobson-Kram D; Lewandowski T; Liteplo R; Pelkonen O; Rice J; Somers D; Turturro A; West W; Olin S
    Crit Rev Toxicol; 2007; 37(9):729-837. PubMed ID: 17957539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A modern approach to toxicologic pathology of the nervous system. Eighth international symposium of the Society of Toxicologic Pathologists. Cincinnati, Ohio, May 21-25, 1989. Proceedings.
    Toxicol Pathol; 1990; 18(1 Pt 2):81-223. PubMed ID: 2367809
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulatory Considerations and Evolving Technologies in Toxicologic Pathology. Proceedings of the Society of Toxicologic Pathologists 12th International Symposium. Alexandria, Virginia, June 27-July 1, 1993.
    Toxicol Pathol; 1994; 22(2):85-225. PubMed ID: 7973373
    [No Abstract]   [Full Text] [Related]  

  • 11. Draft recommendations on classification of rodent neoplasms for Peto analysis.
    Toxicol Pathol; 2001; 29(2):265-8. PubMed ID: 11421495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fifth International Symposium of the Society of Toxicologic Pathologists: "The immune system--toxicology and pathology". May 18-21, 1986, Chicago, Illinois. Proceedings.
    Toxicol Pathol; 1987; 15(3):261-351. PubMed ID: 3685786
    [No Abstract]   [Full Text] [Related]  

  • 13. Renal pathology and toxicity. Fourth International Symposium of the Society of Toxicologic Pathologists, Washington, D.C., June 5-7, 1985.
    Toxicol Pathol; 1986; 14(2):158-262. PubMed ID: 3764312
    [No Abstract]   [Full Text] [Related]  

  • 14. Renal pathology and toxicity. Fourth International Symposium of the Society of Toxicologic Pathologists. Washington, D.C., June 5-7, 1985.
    Toxicol Pathol; 1986; 14(1):11-128. PubMed ID: 3715326
    [No Abstract]   [Full Text] [Related]  

  • 15. [Criteria, rules and procedures adopted by IARC in evaluating risks from different carcinogenic agents for humans].
    IARC
    Vopr Onkol; 2007; 53(6):621-41. PubMed ID: 18416130
    [No Abstract]   [Full Text] [Related]  

  • 16. Animal carcinogenicity studies: implications for the REACH system.
    Knight A; Bailey J; Balcombe J
    Altern Lab Anim; 2006 Mar; 34 Suppl 1():139-47. PubMed ID: 16555967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exact significance levels for multiple binomial testing with application to carcinogenicity screens.
    Brown CC; Fears TR
    Biometrics; 1981 Dec; 37(4):763-74. PubMed ID: 7337794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global recognition of qualified toxicologic pathologists: where we are now and where we need to go.
    Ettlin RA; Bolon B; Pyrah I; Konishi Y; Black HE
    Exp Toxicol Pathol; 2008 Jun; 60(1):1-8. PubMed ID: 18424010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Concerning possible pathways of lead carcinogenicity].
    Il'icheva SA; Zaridze DG
    Vopr Onkol; 2008; 54(3):268-71. PubMed ID: 18652229
    [No Abstract]   [Full Text] [Related]  

  • 20. IARC monograph programme on the evaluation of the carcinogenic risk of chemicals to humans: preamble.
    IARC Monogr Eval Carcinog Risk Chem Hum; 1981 May; 26():11-34. PubMed ID: 6944254
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.